PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 14, 2025Frontiers in Endocrinology4 citationsOpen Access

Screening for primary aldosteronism in 1,181 Swedish primary care patients with hypertension

NMNikita MakhnovJSJakob SkovTÅTobias Åkerström

Key Result

Screening for primary aldosteronism using the aldosterone-renin ratio in primary care patients with hypertension revealed a prevalence of 4.5%, with most cases being mild.

Study Design

Type

Cross-Sectional (n=1,181)

Multicenter

Yes

Structured PICO

P
Population
1,181 Swedish primary care patients with hypertension, aged 18-65 years. Key exclusions: pregnancy, followed in specialized centers, or high-risk conditions for diagnostic protocol (BP >180/110 despite optimization, NYHA class >2, severe respiratory, hepatic, or renal failure).
I
Intervention
Screening for primary aldosteronism using plasma aldosterone-renin ratio (ARR) under current antihypertensive therapy (excluding mineralocorticoid receptor antagonists), confirmed by intravenous saline suppression test, followed by lateralization studies and specific treatment.
O
Outcome
Prevalence of primary aldosteronism

Active screening for primary aldosteronism in primary care patients with hypertension using ARR under current therapy is feasible and identifies a prevalence of 4.5%.

Limitations

  • Did not account for previously diagnosed cases of primary aldosteronism already followed by specialist clinics
  • Several high-risk patients could not complete the full diagnostic process
  • Reliance on the aldosterone-renin ratio for screening may lead to underdiagnosis of the true prevalence

Abstract

Objective: Primary aldosteronism (PA) is a common cause of hypertension. It entails elevated morbidity and mortality that do not sufficiently improve with conventional antihypertensive therapy. Screening for PA by plasma aldosterone-renin ratio (ARR) enables discovery and specific treatment of affected patients. By screening primary care patients with hypertension and evaluating them further according to the Endocrine Society guidelines, we aimed to assess the prevalence of PA, the factors affecting biochemical diagnostics, and the outcome of lateralization studies and of specific treatment of the discovered PA cases. Design patients and methods: Prospective evaluation of screening for PA was conducted in 1,181 patients. Screening by ARR was performed under current therapy, but without mineralocorticoid receptor antagonists (MRA), under normokalemia, and confirmed by the intravenous saline suppression test, SST#1. Those with results in a defined gray zone underwent therapy adjustment and then completed SST#2. Plasma aldosterone and ARR were compared under different stages of the diagnostic process. All patients with PA were offered adrenal venous sampling, or, in certain cases, adrenocortical-specific positron emission tomography. Lateralizing cases were offered laparoscopic adrenalectomy. Patients with bilateral disease were treated with MRA. Treatment results were assessed after a minimum of 6 months. Results: A total of 53 discovered cases of (mostly mild) PA corresponded to its prevalence of 4.5%. Initial seated ARR was higher than recumbent ARR before SST#1. At SST#2, initial ARR and final aldosterone were higher than at SST#1. Localizing studies (accepted by 45 patients) found 14 lateralized cases. Of the 11 operated cases, 4 had aldosterone-producing adenoma, and the remainder had micro- and macronodular histopathology. A total of 31 patients had bilateral PA. Both surgical and conservative treatments were well tolerated and led to improved blood pressure and higher renin, indicating risk amelioration. Conclusions: PA is prevalent among primary care patients with hypertension and can be screened for under current antihypertensive therapy. Aldosterone-producing adenoma was rare in this cohort. The study results support active screening of primary care patients with hypertension for PA in order to offer appropriate treatment options.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Makhnov et al. (2025) conducted a cross-sectional in Hypertension (n=1,181). Screening by aldosterone-renin ratio (ARR) was evaluated on Prevalence of primary aldosteronism. Screening for primary aldosteronism using the aldosterone-renin ratio in primary care patients with hypertension revealed a prevalence of 4.5%, with most cases being mild.

synapsesocial.com/papers/6a1317ce43063096c0de6075https://doi.org/10.3389/fendo.2025.1555572
Ask AI
Helpful
Bookmark
Share
View Full Paper